Patent Application
20060089415
The present invention generally relates to anti-infective agents and specifically to anti-infective agents isolated from Myricaceae family plants, especially Comptonia peregrina (sweet fern).
Myricaceae family plants typically include resinous trees or shrubs having evergreen or deciduous leaves. Family characteristics of plants of the Myricaceae family are well known and established. Such plants include Comptonia peregrina, Comptonia ceterach, Myrica asplenfolia, Liquidamber peregrina, Myrica comptonia, Myrica peregrina, Gale palustris, Myrica gale, Myrica palustris, Myrica cerifera, Myrica pusilla, Cerothammus ceriferus and Cerothammus pusilla.
Comptonia peregrina (L.) Coulter (“sweet fern”) is a shrub of the Myricaceae family. It is also known as Myrica asplenifolia or Myrica peregrina. It is not actually a fern but a low deciduous rhizomatous shrub, with fern-like foliage. It is a woody plant found in the North Woods, New Brunswick, New England, the Great Lakes region, Saskatchewan, Georgia, and North Dakota.
Historically Mi'kmaq used the leaves to treat poison ivy rashes. Plant materials from C. peregrina have also been used as potpourri and tea for relieving symptoms of dysentery. Further, its fruits are eaten as food and the fresh leaves are used as lining for fruit baskets to preserve the fruits.
As well, the Ojibwe of northern Wisconsin and other Indian cultures as well as European settlers and more modern herbalists have used the leaves of this plant in the treatment of stomach ailments and dermatological problems, such as psoraisis, eczema and skin cancers. Previous chemical and biological investigations of this plant described in the literature have primarily focused on the volatile oil and flavonoid components of this plant.
For other diseases, such as bacterial diseases, bacterial resistance is an ever growing problem. For example, see comments by By Linda Brenon on the FDA website <http://www.fda.gov/fdac/features/2002/402_bugs.html>. Bacteria that resist not only single, but multiple, antibiotics have become increasingly widespread—making some diseases particularly hard to control. In fact, according to the Centers for Disease Control and Prevention (CDC), virtually all significant bacterial infections in the world are becoming resistant to the antibiotic treatment of choice. For some patients, bacterial resistance could mean more visits to the doctor, a lengthier illness, and possibly more toxic drugs. For others, it could mean death. The CDC estimates that each year, nearly 2 million people in the United States acquire an infection while in a hospital, resulting in 90,000 deaths. More than 70 percent of the bacteria that cause these infections are resistant to at least one of the antibiotics commonly used to treat them.
Antibiotic resistance, also known as antimicrobial resistance, is not a new phenomenon. Just a few years after the first antibiotic, penicillin, became widely used in the late 1940s, penicillin-resistant infections emerged that were caused by the bacterium Staphylococcus aureus (S. aureus). These “staph” infections range from urinary tract infections to bacterial pneumonia. Methicillin, one of the strongest in the arsenal of drugs to treat staph infections, is no longer effective against some strains of S. aureus. Vancomycin, which is the most lethal drug against these resistant pathogens, may be in danger of losing its effectiveness; recently, some strains of S. aureus that are resistant to vancomycin have been reported.
Although resistant bacteria have been around a long time, the scenario today is different from even just 10 years ago, as suggested by the Alliance for the Prudent Use of Antibiotics. The number of bacteria resistant to many different antibiotics has increased, in many cases, tenfold or more. Even new drugs that have been approved are confronting resistance, fortunately in small amounts.
Accordingly, the need exists for further investigating new drugs such as antibiotics, antimicrobials, compounds and derivatives, which have so far not been discovered to counter increasing bacterial resistance of currently known compounds and derivatives. Of course, the compounds and derivatives of present invention may be used in a multitude of situations where these anti-infective properties and capabilities are desired. Thus, the present invention should not be interpreted as being limited to application in connection with those preferred embodiments described in the present invention.
The present invention provides a compound of Formula I, or a salt or prodrug. Generally, the compound, salt or prodrug is an anti-infective agent useful for the treatment of disease caused by bacteria, and preferably, gram positive bacteria.
Formula I is described as follows:
wherein R1 is not H when R2 is H and R2 is not H when R1 is H, further wherein R1 is CH(2n+1)O, wherein n is 1-10; wherein R2 is OH or CH(2n+1)O, wherein n is 1-10; and wherein A, B and R1, R2, R5, R6, and R7 are independently selected from a group consisting of H, alkyl and aryl groups and R11 is an alkyl or an aryl group.
In a preferred embodiment, the compound, salt or prodrug is according to Formula II.
wherein R1 is not H when R2 is H and R2 is not H when R1 is H, further wherein R1 is CH(2n+1)O, wherein n is 1-10; wherein R2 is OH or CH(2n+1)O, wherein n is 1-10; and wherein A, B and R3 through R10 are independently selected from a group consisting of H, alkyl and aryl groups.
In a preferred embodiment, R1 is CH3O and R2 is OH or CH(2n+1)O, wherein n is 1-10; and wherein A, B and R3 through R10 are independently selected from a group consisting of H, alkyl and aryl groups.
In another preferred embodiment, R1 is CH3O, R2 is OH and wherein A, B and R3 through R10 are independently selected from a group consisting of H, alkyl and aryl groups.
Further, said compound, salt or prodrug may have an E or Z orientation. Most preferably, compound of Formula 1 is:
or salt and prodrug thereof.
Another aspect of the invention teaches a method of isolating an anti-infective compound from a Myricaceae family plant. In one embodiment, the plant is Comptonia peregrina, Comptonia ceterach, Myrica asplenfolia, Liquidamber peregrina, Myrica comptonia, Myrica peregrina, Gale palustris, Myrica gale, Myrica palustris, Myrica cerifera, Myrica pusilla, Cerothammus ceriferus or Cerothammus pusilla. The method comprises the steps of (a) collecting a plant material (b) extracting crude extract from the plant material; and (c) isolating and purifying at least one anti-infective compound from the crude extract. Preferably, the plant material includes leaves of C. peregrina plant. Further, in a preferred embodiment, the isolation and purification are carried out by chromatography. In a more preferred embodiment, the isolated anti-infective compound is E or Z-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene.
Yet another aspect of the present invention describes a method of treating infections or inhibiting microbial growth in a subject in need thereof, said method comprising the step of administering an effective amount of a compound having a structure represented by Formula I or a salt or prodrug thereof. Such infections may be caused by a bacterium.
Another aspect of the invention provides a pharmaceutical composition, comprising: (a) an effective amount of a compound having a chemical structure represented by Formula I, or a salt or a prodrug thereof; and (b) a pharmaceutically-acceptable carrier. The compound, salt or prodrug is an anti-infective agent useful for the treatment of disease caused by a bacterium.
Yet another aspect of the invention provides a method of inhibiting microbial growth. The method comprising contacting microbe to be inhibited with a microbial inhibiting amount of a compound according to Formula I, or salt or prodrug thereof.
Preferably the microbe to be inhibited is selected from the group consisting of: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, Bacillus cereus, Helicobacter pylori, Bacillus megaterium, Bacillus subtilis, Corynebacterium pseudodipthericum, Corynebacterium diphtheriae tox, Corynebacterium xerosis, Enterococcus faecium VRE 1, Enterococcus faecium VRE 14, Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 29213, Staphylococcus aureus ATCC 25923, Staphylococcus aureus MRSA MC-1, Staphylococcus aureus MRSA MC-4, Streptococcus mitis, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus pneumoniae ATCC 49619, Listeria monocytogenes, Mycobacterium bovis BCG, Mycobacterium tuberculosis, and Bacillus anthracis. Further, the microbe to be inhibited is a gram positive bacterium. In certain embodiments, the bacterium is a gram positive bacterium or a Mycobacterium.
Another aspect of the invention provides a composition suitable for inhibiting growth of microbes. The composition comprises: a first ingredient which inhibits microbial growth comprising the compound, prodrug or salt of claim 1; and a second ingredient which comprises an acceptable carrier or an article of manufacture. In one embodiment, the acceptable carrier is a pharmaceutically acceptable carrier, an antibacterial agent, a skin conditioning agent, a lubricating agent, a coloring agent, a moisturizing agent, binding and anti-cracking agent, a perfuming agent, a brightening agent, a UV absorbing agent, a whitening agent, a transparency imparting agent, a thixotropic agent, a solubilizing agent, an abrasive agent, an antioxidant, a skin healing agent, a cream, a lotion, an ointment, a shampoo, an emollient, a patch a gel or a sol. In another embodiment, the article of manufacture is a textile, a fiber, a glove or a mask. Preferably, in the composition, the first ingredient is E or Z-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene.
In sum, the present invention represents new compounds and methods of using these compounds for the treatment and prevention of various infections and growth of microbes. These and other objects and advantages of the present invention will become apparent from the detailed description accompanying the drawings.
General:
Before the present methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a compound” includes a plurality of such compounds and equivalents thereof known to those skilled in the art, and so forth. As well, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the terms “comprising”, “including”, and “having” can be used interchangeably.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the chemicals, cell lines, vectors, animals, instruments, statistical analysis and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
As defined herein, the term “isomer” includes, but is not limited to strereoisomers and analogs, structural isomers and analogs, conformational isomers and analogs, and the like. In one embodiment, this invention encompasses the use of different stereoisomers of an anti-infective compound of Formula I. It will be appreciated by those skilled in the art that the anti-infective compounds useful in the present invention may contain a chiral center. Accordingly, the compounds used in the methods of the present invention may exist in, and be isolated in, optically-active or racemic forms. Some compounds may also exhibit polymorphism. It is to be understood that the present invention encompasses the use of any racemic, optically-active, polymorphic, or stereroisomeric form, or mixtures thereof, which form possesses properties useful in the treatment of microbial infection-related conditions described and claimed herein. In one embodiment, the anti-infective compounds are the pure (Z) or (E)-isomers. In another embodiment, the anti-infective compounds are the pure (R) or (S)-isomers. In another embodiment, the compounds are a mixture of the (R) and the (S) isomers or (E) and (Z) isomers. In another embodiment, the compounds are a racemic mixture comprising an equal amount of the (R) and the (S) isomers. Furthermore, where the compounds according to the invention have at least one asymmetric center, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention. Preparation of these isomers, compounds and derivatives are well known to one of ordinary skill in the art.
The invention includes the use of pharmaceutically acceptable salts of amino-substituted compounds with organic and inorganic acids, for example, citric acid and hydrochloric acid. The invention also includes N-oxides of the amino substituents of the compounds described herein. Pharmaceutically acceptable salts can also he prepared from the phenolic compounds by treatment with inorganic bases, for example, sodium hydroxide. Also, esters of the phenolic compounds can be made with aliphatic and aromatic carboxylic acids, for example, acetic acid and benzoic acid esters. As used herein, the term “pharmaceutically acceptable salt” refers to a compound formulated from a base compound which achieves substantially the same pharmaceutical effect as the base compound.
An active component can be formulated into the composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid addition salts, which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
Pharmaceutically acceptable salts for topical administration to body surfaces using, for example, creams, gels, drops, and the like, include the anti-infective compounds or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are prepared and applied as solutions, suspensions, or emulsions in a physiologically acceptable diluent with or without a pharmaceutical carrier.
This invention further includes method utilizing derivatives of the anti-infective compounds. The term “derivatives” includes but is not limited to ether derivatives, acid derivatives, amide derivatives, ester derivatives and the like. In addition, this invention further includes methods utilizing hydrates of the anti-infective compounds. The term “hydrate” includes but is not limited to hemihydrate, monohydrate, dihydrate, trihydrate and the like.
This invention further includes methods of utilizing metabolites of the anti-infective compounds. The term “metabolite” means any substance produced from another substance by metabolism or a metabolic process.
The present invention includes within its scope prodrugs of the anti-infective compound. In general, such prodrugs will be functional derivatives of the compound of Formula (I) which are readily convertible in vivo into the required compound of Formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
As defined herein, “contacting” means that the anti-infective compound used in the present invention is introduced into a sample containing the receptor in a test tube, flask, tissue culture, chip, array, plate, microplate, capillary, or the like, and incubated at a temperature and time sufficient to permit binding of the anti-infective compound to a receptor. Methods for contacting the samples with the anti-infective compound or other specific binding components are known to those skilled in the art and may be selected depending on the type of assay protocol to be run. Incubation methods are also standard and are known to those skilled in the art.
In another embodiment, the term “contacting” means that the anti-infective compound used in the present invention is introduced into a subject receiving treatment, and the compound is allowed to come in contact in vivo. In yet another embodiment, “contacting” includes topical application of the anti-infective agent on a subject.
As used herein, the term “treating” includes preventative as well as disorder remittent treatment. As used herein, the terms “reducing”, “suppressing” and “inhibiting” have their commonly understood meaning of lessening or decreasing. As used herein, the term “progression” means increasing in scope or severity, advancing, growing or becoming worse. As used herein, the term “recurrence” means the return of a disease after a remission.
In the treatment of infections, minimum inhibitory concentrations (MIC) of a preferred compound of the present invention are shown in Table II. Accordingly, suitable dosage level or an effective amount may be calculated to be about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, or on a continuous basis via, for example, the use of a transdermal patch.
As used herein, the term “administering” refers to bringing a patient, tissue, organ or cells in contact with an anti-infective compound according to Formula I. As used herein, administration can be accomplished in vitro, i.e. in a test tube, or in vivo, i.e. in cells or tissues of living organisms, for example, humans. In certain embodiments, the present invention encompasses administering the compounds useful in the present invention to a patient or subject. A “patient” or “subject”, used equivalently herein, refers to a mammal, preferably a human or an animal, that either: (1) has a microbial infection remediable or treatable by administration of the anti-infective according to Formula I; or (2) is susceptible to a microbial infection that is preventable by administering the anti-infective compound according to Formula I.
In yet another method according to the invention, a pharmaceutical composition can be administered in a controlled release system. For example, the agent may be delivered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In one embodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989). In another embodiment, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in proximity to the therapeutic target, i.e., the skin, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984). Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990).
Also encompassed by the invention are methods of administering particulate compositions coated with polymers (e.g., poloxamers or poloxamines). Other embodiments of the compositions incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including topical, parenteral, pulmonary, nasal and oral. In one embodiment the pharmaceutical composition is administered parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially intrathecally, sublingually, rectally, vaginally, nasally, by inhalation, cutaneously, topically and systemically.
The pharmaceutical preparations administerable by the invention can be prepared by known dissolving, mixing, granulating, or tablet-forming processes. For oral administration, the anti-infective compounds or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions. Examples of suitable inert vehicles are conventional tablet bases such as lactose, sucrose, or cornstarch in combination with binders such as acacia, cornstarch, gelatin, with disintegrating agents such as cornstarch, potato starch, alginic acid, or with a lubricant such as stearic acid or magnesium stearate.
Examples of suitable oily vehicles or solvents are vegetable or animal oils such as sunflower oil or fish-liver oil. Preparations can be effected both as dry and as wet granules. For parenteral administration (subcutaneous, intravenous, intraarterial, or intramuscular injection), the anti-infective compounds or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are converted into a solution, suspension, or expulsion, if desired with the substances customary and suitable for this purpose, for example, solubilizers or other auxiliaries. Examples are sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.
The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. It is also envisioned that the compounds of the present invention may be incorporated into transdermal patches designed to deliver the appropriate amount of the drug in a continuous fashion. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture for a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be easily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example, 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage from affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which, serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
As used herein, “pharmaceutical composition” means therapeutically effective amounts of the anti-infective compound together with suitable diluents, preservatives, solubilizers, emulsifiers, and adjuvants, collectively “pharmaceutically-acceptable carriers.” As used herein, the terms “effective amount” and “therapeutically effective amount” refer to the quantity of active therapeutic agent sufficient to yield a desired therapeutic response without undue adverse side effects such as toxicity, irritation, or allergic response. The specific “effective amount” will, obviously, vary with such factors as the particular condition being treated, the physical condition of the subject, the type of animal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives. In this case, an amount would be deemed therapeutically effective if it resulted in one or more of the following: (a) the prevention of microbial infections; and (b) the reversal or stabilization of microbial infections. The optimum effective amounts can be readily determined by one of ordinary skill in the art using routine experimentation.
Pharmaceutical compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, milamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance. Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils).
The liquid forms in which the pharmaceutical compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium caboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin. Thus for example, in a preferred example, liquid form of the novel composition will include oral rinse solutions, anti-caries solutions, disinfectant solutions, and other liquids forms well known to one of ordinary skill in the art.
The preparation of pharmaceutical compositions which contain an active component is well understood in the art. Such compositions may be prepared as aerosols delivered to the nasopharynx or as injectables, either as liquid solutions or suspensions; however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified. The active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like or any combination thereof.
In addition, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.
Other embodiments of the compositions administered according to the invention incorporate particulate forms, protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.
In another method according to the invention, the active compound can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, N.Y., pp. 353-365 (1989); Lopez-Berestein ibid., pp. 317-327; see generally ibid).
The pharmaceutical preparation can comprise the anti-infective compound alone, or can further include a pharmaceutically acceptable carrier, and can be in solid or liquid form such as tablets, powders, capsules, pellets, solutions, suspensions, elixirs, emulsions, gels, creams, or suppositories, including rectal and urethral suppositories. Pharmaceutically acceptable carriers include gums, starches, sugars, cellulosic materials, and mixtures thereof. The pharmaceutical preparation containing the anti-infective compound can be administered to a subject by, for example, subcutaneous implantation of a pellet. In a further embodiment, a pellet provides for controlled release of anti-infective compound over a period of time. The preparation can also be administered by intravenous, intraarterial, or intramuscular injection of a liquid preparation oral administration of a liquid or solid preparation, or by topical application. Administration can also be accomplished by use of a rectal suppository or a urethral suppository.
Further, as used herein “pharmaceutically acceptable carriers” are well known to those skilled in the art and include, but are not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer or 0.9% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
Pharmaceutically acceptable parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and the like.
Pharmaceutically acceptable carriers for controlled or sustained release compositions administerable according to the invention include formulation in lipophilic depots (e.g. fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g. poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors.
Pharmaceutically acceptable carriers include compounds modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et al., 1981; Newmark et al., 1982; and Katre et al., 1987). Such modifications may also increase the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. As a result, the desired in vivo biological activity may be achieved by the administration of such polymer-compound abducts less frequently or in lower doses than with the unmodified compound.
The inventors have found a compound isolated from Comptonia peregrina that shows selective anti-infective activity against several clinically relevant microorganisms. Furthermore, the inventors have found that crude ethanolic extracts of the leaves of C. peregrina, and the methanol- and methylene chloride-soluble fractions of the crude extract to generally inhibit the growth of several organisms, as shown in Table I using disc diffusion assay.
Upon chromatographic separation of the crude extracts, this activity was ascribed to two compounds, one present in larger amount with a lower chromatographic Rf value (termed the “major” or “low Rf” product), and another present in a lesser amount with a higher chromatographic Rf value (termed the “minor” or “high Rf” product). In the following examples, the major or low Rf compound found in C. peregrina was studied. Structure elucidation and purification of the major compound resulted in identification of a compound, having an IUPAC nomenclature of E-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene.
Following extensive chromatographic purification of the major/low compound, the mass and structural data were determined by GC-MS, IR and NMR methods. Once isolated, the minimum inhibitory concentrations (MIC) of the pure major/low compound were determined against several significant bacteria. The results of these MIC assays are presented in Table 2.
ATCC = American Type Culture Collection;
MRSA = methicillin-resistant Staphylococcus aureus;
VRE = Vancomycin-resistant enterococci
Accordingly, the present invention provides anti-infective compound of Formula I, or a salt or prodrug useful for the treatment of disease caused by a microbe. Preferably, the microbe is a bacterium, and more preferably, a gram positive bacterium. Formula I is shown as follows:
wherein R1 is not H when R2 is H and R2 is not H when R1 is H, further wherein R1 is Cl(2n+1)O, wherein n is 1-10; wherein R2 is OH or CH(2n+1)O, wherein n is 1-10; and wherein A, B and R1, R2, R5, R6, and R7 are independently selected from a group consisting of H, alkyl and aryl groups and R11 is an alkyl or an aryl group.
In a preferred embodiment, the compound, salt or prodrug is according to Formula II.
wherein R1 is not H when R2 is H and R2 is not H when R1 is H, further wherein R1 is CH(2n+1)O, wherein n is 1-10; wherein R2 is OH or CH(2n+1)O, where n is 1-10; and wherein A, B and R3 through R10 are independently selected from a group consisting of H, alkyl and aryl groups.
In a preferred embodiment, R1 is CH3O, R2 is OH or CH(2n+1)O, where n is 1-10; and A, B and R3 through R10 are independently selected from a group consisting of H, alkyl and aryl groups.
In another preferred embodiment, R1 is CH3O, R2 is OH and A, B and R3 through R10 are independently selected from a group consisting of H, alkyl and aryl groups.
Further, said compound, salt or prodrug may have an E or Z orientation. Most preferably, the anti-infective compound is shown as:
or a salt or prodrug thereof.
As used herein “alkyl” group refers to a straight chain, branched or cyclic, saturated or unsaturated aliphatic hydrocarbons. The alkyl group has 1-16 carbons, and may be unsubstituted or substituted by one or more groups selected from halogen, hydroxy, alkoxy carbonyl, amido, alkylamido, dialkylamido, nitro, amino, alkylamino, dialkylamino, carboxyl, thio and thioalkyl. A “hydroxy” group refers to an OH group. An “alkoxy” group refers to an —O-alkyl group wherein alkyl is as defined above. A “thio” group refers to an —SH group. A “thioalkyl” group refers to an —SR group wherein R is alkyl as defined above. An “amino” group refers to an —NH2 group. An “alkylamino” group refers to an —NHR group wherein R is alkyl is as defined above. A “dialkylamino” group refers to an —NRR′ group wherein R and R′ are all as defined above. An “amido” group refers to an —CONH2. An “alkylamido” group refers to an —CONHR group wherein R is alkyl is as defined above. A “dialkylamido” group refers to an —CONRR′ group wherein R and R′ are alkyl as defined above. A “nitro” group refers to an NO2 group. A “carboxyl” group refers to a COOH group.
As used herein, “aryl” includes both carbocyclic and heterocyclic aromatic rings, both monocyclic and fused polycyclic, where the aromatic rings can be 5- or 6-membered rings. Representative monocyclic aryl groups include, but are not limited to, phenyl, furanyl, pyrrolyl, thienyl, pyridinyl, pyrimidinyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl and the like. Fused polycyclic aryl groups are those aromatic groups that include a 5- or 6-membered aromatic or heteroaromatic ring as one or more rings in a fused ring system. Representative fused polycyclic aryl groups include naphthalene, anthracene, indolizine, indole, isoindole, benzofuran, benzothiophene, indazole, benzimidazole, benzthiazole, purine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, pteridine, carbazole, acridine, phenazine, phenothiazine, phenoxazine, and azulene.
As used herein, aryl group also includes an arylalkyl group. Further, as used herein “arylalkyl” refers to moieties, such as benzyl, wherein an aromatic is linked to an alkyl group which is linked to the indicated position in the compound of Formula 1.
Another aspect of the invention teaches a method of isolating an anti-infective compound from a Myricaceae family plant. In one embodiment, the plant is Comptonia peregrina, Comptonia ceterach, Myrica asplenfolia, Liquidamber peregrina, Myrica comptonia, Myrica peregrina, Gale palustris, Myrica gale, Myrica palustris, Myrica cerifera, Myrica pusilla, Cerothammus ceriferus or Cerothammus pusilla. The method comprises the steps of (a) collecting a plant material (b) extracting crude extract from the plant material; and (c) isolating and purifying at least one anti-infective compound from the crude extract. Preferably, the plant material includes leaves of C. peregrina plant. Further, in a preferred embodiment, the isolation and purification are carried out by chromatography. In a more preferred embodiment, the isolated anti-infective compound is E or Z-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene. While the anti-infective agent is preferably extracted from a Myricaceae family plant, other known plants may also provide the anti-infective compound.
Yet another aspect of the present invention describes a method of treating infections or inhibiting microbial growth in a patient in need thereof, said method comprising the step of administering an effective amount of a compound having a structure represented by Formula I or a salt or prodrug thereof. Such infections may be caused by a bacterium.
Another aspect of the invention provides a pharmaceutical composition, comprising: (a) an effective amount of a compound having a chemical structure represented by Formula I, or a salt or a prodrug thereof; and (b) a pharmaceutically-acceptable carrier. The compound salt or prodrug is an anti-infective agent useful for the treatment of disease caused by a bacterium. Most preferably, the bacterium is a gram positive bacterium.
Yet another aspect of the invention provides a method of inhibiting microbial growth. The method comprising contacting microbe to be inhibited with a microbial inhibiting amount of a compound according to Formula I, or salt or prodrug thereof.
Preferably the microbe to be inhibited is a bacterium. Further, the bacterium to be inhibited is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, Bacillus cereus, Helicobacter pylori, Bacillus megaterium, Bacillus subtilis, Corynebacterium pseudodipthericum, Corynebacterium diphtheriae tox, Corynebacterium xerosis, Enterococcus faecium VRE 1, Enterococcus faecium VRE 14, Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 29213, Staphylococcus aureus ATCC 25923, Staphylococcus aureus MRSA MC-1, Staphylococcus aureus MRSA MC-4, Streptococcus mitis, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus pneumoniae ATCC 49619, Listeria monocytogenes, Mycobacterium bov/s BCG, Mycobacterium tuberculosis, and Bacillus anthracis. In certain embodiments, the bacterium is a gram positive bacterium or a Mycobacterium.
The invention also provides a composition suitable for inhibiting growth of microbes. The composition comprises: a first ingredient which inhibits microbial growth comprising the compound, prodrug or salt of claim 1; and a second ingredient which comprises an acceptable carrier or an article of manufacture. Preferably, in the composition, the first ingredient is E or Z-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene.
In one embodiment, the acceptable carrier is an antibacterial agent, a skin conditioning agent, a lubricating agent, a coloring agent, a moisturizing agent, binding and anti-cracking agent, a perfuming agent, a brightening agent, a UV absorbing agent, a whitening agent, a transparency imparting agent, a thixotropic agent, a solubilizing agent, an abrasive agent, an antioxidant, a skin healing agent, a cream, a lotion, an ointment, a shampoo, an emollient, a patch a gel, a sol or other pharmaceutically acceptable carriers as described above. In another embodiment, the article of manufacture is a textile, a fiber, a glove or a mask. Therefore the composition in combination with the article of manufacture will provide anti-infective textiles and fibers, or anti-infective gloves and masks, useable in medical facilities, and other locations where anti-infective properties are desirable. Furthermore, the microbe inhibiting composition will include anti-caries solution, oral rinse solutions, anti-microbial cosmetic applications, anti-microbial soaps, sprays, cleaning solutions, detergents, and other applications where the anti-infective properties are desirable. Compositions, methods and techniques for using the acceptable carriers and articles of manufacture are well known to one of ordinary skill in the art.
Following examples are related to the compounds and methods of the present invention and are put forth for illustrative purposes only. These examples are not intended to limit the scope of the invention.
The stems and leaves of C. peregrina were collected from various northern Wisconsin locales during the summer months of June-September and air dried in closed paper bags to protect the plant material from exposure to light. In an exemplary preparation, the leaves of C. peregrina were separated from the woody stems, and 163.69 g of this dried leaf material was placed in a cellulose extraction thimble. The plant material was subjected to continuous extraction for 24 hours using a Soxhlet extractor and methylene chloride (CH2Cl2) as the solvent. After removal of the solvent under reduced pressure and thorough drying the crude leaf extract was obtained as a sticky brown gum that weighed 8.87 g (5.4%).
The crude extract was then fractionated by flash column chromatography, using a 42 mm ID column, silica gel 60 as the stationary phase, and CH2Cl2 as the eluting solvent. Typically, 100-150, 10 mL fractions were collected and assayed for microbial growth inhibition. This bioassay-directed fractionation allowed for the identification of a major component, “CL-low,” that inhibited the growth of several strains of bacteria in the Kirby-Bauer disc diffusion assay. The column fractions, including the active component, were also analyzed by thin-layer chromatography (TLC) using Baker-flex® silica gel IB2-F plates (with fluorescent indicator) and CH2Cl2 as the eluting solvent (see
All column fractions containing the active CL-low component were pooled, and this component was purified and isolated by successive, preparative TLC, using CH2Cl2 as the solvent.
In another preferred embodiment, HPLC Assay for CL Low was performed as shown below:
Sample Preparation: Dried samples extracted from TLC plates are dissolved in a minimal volume of methylene chloride and diluted to approximately 20 A290/ml with isopropanol. Absorbance at 290 nm is close to the UV maximum for CL Low.
Column and Conditions: The assay is run on a 4.6 mm×300 mm Aligent C-8 HPLC column. The elution buffer is Methanol:1% acetic acid in water (65%/35%) run isocratically. Flow rate is 1.25 ml/min.
Assay Analysis: The Waters HPLC system has a diode array detector that allows analysis at several wavelengths during the run. A 15 μl sample is injected and the column is monitored at 254 nm and 290 nm.
Additional information: Spectra may be analyzed across a given peak to insure that the peak is pure (i.e., the spectra at the leading edge of the peak looks the same as at the end of the peak). The amount of material injected may also be adjusted to so that peak heights are about 1 Absorbance unit in height. Once the HPLC assay is run, the controls and standards may be run. Preferably, the controls and standards are run both before and the HPLC runs.
In the chromatograph as shown in
Methods: Methylene chloride extracts of the dried leaves of C. peregrina were initially screened for anti-microbial activity with disk diffusion assays (DDAs) against four indicator bacterial species. Successive flash column and thin layer chromatography were used to partition the crude extract into fractions that were tested for activity using DDAs against Staphylococcus epidermidis. An active compound was purified, and its structure was obtained using IR, GC-MS, and NMR analyses. Using NCCLS guidelines, DDAs and minimum inhibitory concentration (MIC) assays were performed against clinically significant Gram-positive bacterium. Isoniazid was used as a control for MIC assays performed with Mycobacterium bovis strain BCG. Tetracycline and rifampin were used as controls against all other bacterial species tested to ensure validity of the MIC assays.
Results: Structural analysis indicates the active compound is E-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene. This compound was found to inhibit the growth of all Gram-positive bacteria tested, including vancomycin-resistant enterococci (MIC 32 μg/mL), methicillin-resistant Staphylococcus aureus (MIC 32 μg/mL) and M. bovis (MIC 25.6 μg/mL). The compound did not show significant activity against the Gram-negative bacteria tested (MICs >128 μg/mL).
Conclusion: A novel anti-bacterial compound isolated from C. peregrina possesses broad-spectrum activity against clinically important Gram-positive bacterial species.
Bacillus anthracis
Furthermore, the species Bacillus cereus and Bacillus anthracis have been shown to have extensive homologies at the DNA (Read et al., 2003) and protein (Gohar et al., 2005) levels. Most of the differences that are attributed to these species can be explained by the presence of separate virulence plasmids in each species. In terms of screening with known antibiotics, both species do have some common susceptibility patterns against ciprofloxacin and gentamicin (Turnbull et al., 2004). Differences in susceptibility patterns were noted for penicillin and erythromycin (B. anthracis typically susceptible and B. cereus typically resistant). The penicillin susceptibility results in B. anthracis are due to a truncation of a positive regulatory gene, not because of a lack of β-lactamase genes (Read et al., 2003). For screening against new classes of antibiotics, both species are likely to show the same susceptibility patterns as a result of their structural similarities. (These similarities and difference have been discussed in literature, as shown in Gohar et al. 2005. A comparative study of Bacillus cereus, Bacillus thurgiensis, and Bacillus anthracis extracellular proteomes. Proteomics 5:3696-3711; Read et al. 2003.) The genome sequence of Bacillus anthracis Ames strain and comparisons to closely related bacterium. Nature 423:81-86; and Turnbull et al. 2004. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J. Clin. Microbiol. 42:3626-3634, which are incorporated herein by reference for all purposes.
Mycobacterium bovis BCG
The active compound is E-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene may also be highly effective in treating tuberculosis. The purified extract was screened against Mycobacterium bovis BCG, a virulent, slow growing, BSL level 2/3 pathogen, closely analogous to M. tuberculosis. The minimum inhibitory concentration (MIC) in this assay was found to be 25.6 μg/mL.
A pure sample of CL-low was obtained as a yellow, waxy solid, and this was analyzed spectroscopically (GC-MS, IR, and NMR) and found to have a molecular mass of 242.4 g/mol and molecular formula, C15H14O3. On the basis of the available spectral information, the chemical structure of CL-low is:
IUPAC nomenclature of the CL-low compound was determined to be E-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene.
The material from Example I was characterized by using numerous analytical chemistry tools such as MS, IR, 1H-NMR and 13C-NMR. In MS, following observations were made: MS (m/z): Molecular ion, M+, 242 g/mol=C15H14O3. Major fragments at: 227 g/mol (indicated loss of 15 g/mol, methyl group, —CH3) and 149 g/mol (indicated loss of 93, g/mol, phenoxy group, —OPh)
IR observations were made to further characterize and elucidate the structure of the active ingredient, for example a strong, broad absorption at 3384 cm−1 indicated presence of —OH group (phenol).
Further, 1H-NMR (δppm) produced the following observations: 3.85, s, 3H; —OCH3; 5.05, bs; 1H, —OH 6.35; 1H, t, (J=1.5 Hz) Hc 6.61, 1H, t, (J=1.5 Hz), Ha 6.66, 1H, t, (J=1.5 Hz), Hb 7.03, 2H, q, (J=16 Hz, trans), 2 vinyl protons of trans-/E-alkene 7.27, 1H, t, (J=7.5 Hz), Hp 7.36, 2H, t, (J=1.5 Hz), Hm 7.50, 2H, d, (J=7.5 Hz), Ho
Finally 13C-NMR (δppm) produced the following observations: 55, —OCH3 101, CH, (vinyl carbon near the substituted arene) 105, CH 107, CH 126.5, CH×2 (identical, 2 carbons at Ho) 127.8, CH 128.3, CH 128.7, CH×2 (identical, 2 carbons at Hm) 129.4, CH 137, 140, 156, 162, C×4 (4 unsubstituted aromatic carbons).
In the most preferred embodiment, the present compound was determined to be E-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene.
The chemical synthesis depicted herein is only for illustrative purposes and should not be deemed to limit the scope of present invention. Accordingly, compound E-1-(2-phenoxyethenyl)-3-hydroxy-5-methoxybenzene may be chemically synthesized in a laboratory setting using skills known to one of ordinary skill in the art. See Surendra et al., Highly Regioselective Ring Opening of Oxiranes with Phenoxides in the Presence of a Cyclodextrin in Water J. Org. Chem. 2003, 68, 4994-95, which is incorporated herein by reference for all purposes. The synthetic method generally comprises adding a suitable oxirane to a suitable phenol in the presence of a suitable base to produce the desired compound as shown schematically:
The starting compounds, including the oxirane and the phenol may be substituted to result in various substituted compounds, by methods and techniques well known to one of ordinary skill in the art. These starting compounds are available commercially or may be synthesized in laboratory settings, without undue experimentation.
General Synthetic Method
The natural product, CL-low, and its many possible ring-substituted analogs may be prepared according to the general scheme above. As an example synthesis, the specific experimental method for preparing the unsubstituted scaffold, phenoxystyrene (CL-4), is detailed below.
In general, sodium phenoxide, as well as its ring-substituted analogs, may be prepared from the corresponding phenol using the method of Kornblum and Lurie. Kornblum, N., Lurie, A. P. Heterogeneity as a Factor in the Alkylation of Ambident Anions: Phenoxide Ions,” J. Am. Chem. Soc., 1959; 81(11), 2705-2715. The sodium phenoxide salt may then be reacted with styrene oxide, or its ring-substituted analogs, according to the procedure of Guss to provide 1-phenyl-2-phenoxyethanol, as well as its ring-substituted analogs. Finally, dehydration of the benzylic alcohol under acidic conditions, yields (E)-beta-phenoxystyrene, as well its ring-substituted analogs. See Guss, C. “The Reaction of Styrene Oxide with Phenol,” J. Am. Chem. Soc., 1949, 71, 3460-3462.
Materials and Methods
Sodium phenoxide. Phenol (50.0 g) was dissolved in 70 mL of methanol and added, with stirring, to 21.3 g of NaOH dissolved in 300 mL of an 85% methanol-water solution. The solvent was removed under reduced pressure, and the residual solid was ground using a mortar and pestle and dried under vacuum. This grinding and drying was repeated until a constant weight was achieved to yield 61.0 g (98.9%) of sodium phenoxide as a white solid which was sufficiently pure to use in the following step.
1-Phenyl-2-phenoxyethanol (CL-3). Solid sodium phenoxide (12.7 g) was added, with stirring, to 15 mL of DMF at 110° C. (See Guss, C. “The Reaction of Styrene Oxide with Phenol,” J. Am. Chem. Soc., 1949, 71, 3460-3462.) Once the temperature returned to 105° C., 12.4 g of styrene oxide in 15 mL of DMF was added dropwise over 15 min. The addition funnel was replaced with a water cooled condenser, and the reaction mixture was held at reflux for one hour. The flask contents were poured into 500 mL of ice water and extracted with 3×50 mL of ethyl acetate. The organic extracts were pooled and washed sequentially with dilute NAOH, water, and brine, dried with MgSO4, and filtered through celite. Evaporation of the solvent yielded 22.45 g of a dark orange oil that solidified upon standing at room temperature. The solid was distilled under reduced pressure (0.1 mm Hg, 150° C.) to yield a colorless oil that crystallized upon standing at 4° C. Recrystallization from ethyl acetate/hexane gave 12.4 g (55.4%) of 1-phenyl-2phenoxyethanol as white needles: mp 61-62° C. (lit.2 mp 63-64° C.); 1H NMR δ 2.85 (bs, 1H, ArCHOH), 4.10 (m, 2H, ArOCH2), 5.15 (dd, 1H, ArCHOH), 6.95 (d, 3H ArH), 7.40 (m, 7H, ArH); FTIR 1242 cm−1, 1456 cm−1, 1584 cm−1, 2854 cm−1, 3202 cm−1; GC retention time 13.29 min; CIMS m/z 214 (M+), 197, 108, 94, 77.
(E)-β-Phenoxystyrene (CL-4). Concentrated H3PO4 (1 mL) was added to 50 mL of hexanes held at reflux in a three-neck round bottom flask equipped with a Dean-Stark trap and thermometer. After 20 min of stirring to remove water from the system, 2.00 g of 1-phenyl-2-phenoxyethanol in 5 mL of CH2Cl2 was added over two min. The system was vented to allow vaporization and escape of the volatile CH2Cl2. The suspension was stirred at reflux for four hours, poured into 200 mL of ice water, and extracted with 3×50 mL of ethyl acetate. The organic extracts were pooled and washed sequentially with dilute NaOH, H2O, and brine. The organic phase was dried with MgSO4, and the solvent was removed under reduced pressure. Purification by silica gel flash column chromatography with CH2Cl2 as the mobile phase yielded 1.22 g (66.7%) of the phenoxystyrene as a white, waxy solid. 1H NMR δ 6.74-6.82 (dd, 2H, Ar—CH═CH), 6.92 (d, 1H, ArH), 7.18 (m, 9H, ArH); FTIR 1228 cm−1, 1597 cm−1, 3028 cm−1, 3061 cm−1; GC retention time 11.93 min; CIMS m/z 196 (M+).
The compounds and a method of extracting these anti-infective agents of the present invention may have other applications aside from use anti-infective agents. Additionally, it would be apparent to one of ordinary skill in the art to alter the methods and compositions which have been described herein in the preferred embodiment. Such alterations include altering the starting compound and making substitutions, without departing from the spirit of the invention, or altering the stereochemistry and conformations of the compounds. Further alterations include creating salts and prodrugs of these compounds by techniques and methods known to one of ordinary skill in the art.
Thus, although the invention has been herein shown and described in what is perceived to be the most practical and preferred embodiments, it is to be understood that the invention is not intended to be limited to the specific embodiments set forth above. Rather, it is recognized that modifications may be made by one of skill in the art of the invention without departing from the spirit or intent of the invention and, therefore, the invention is to be taken as including all reasonable equivalents to the subject matter of the appended claims.
Present invention seeks priority from U.S. Provisional Application No. 60/522,587 filed on Oct. 18, 2004, which is incorporated herein by reference for all purposes.
| Number | Date | Country | |
|---|---|---|---|
| 60522587 | Oct 2004 | US |
